Royalty Pharma PLC (RPRX): A Strategic SWOT Insight [Yahoo! Finance]
Royalty Pharma plc - Class A Ordinary Shares (RPRX)
US:NASDAQ Investor Relations:
ir.reprosrx.com/investor-relations
Company Research
Source: Yahoo! Finance
Market competition and regulatory changes pose significant threats. Proactive share repurchase program reflects confidence in long-term value. On November 6, 2024, Royalty Pharma PLC ( NASDAQ:RPRX ), the industry-leading acquirer of biopharmaceutical royalties, filed its 10-Q report, revealing the latest financials and strategic insights. With a portfolio that includes royalties on over 35 commercial products and 10 development-stage candidates, RPRX stands out for its unique business model. The financial tables from the filing indicate a solid balance sheet, with dividends to Class A shareholders increasing to $282.8 million in the first nine months of 2024, up from $269.0 million in the same period of 2023. Additionally, RPRX's share repurchase program, with $179.7 million spent on buybacks in the first nine months of 2024, signals a strong commitment to shareholder value. This SWOT analysis delves into the strengths, weaknesses, opportunities, and threats as disclosed in the r
Show less
Read more
Impact Snapshot
Event Time:
RPRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RPRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RPRX alerts
High impacting Royalty Pharma plc - Class A Ordinary Shares news events
Weekly update
A roundup of the hottest topics
RPRX
News
- The Leukemia & Lymphoma Society (LLS) Data at ASH Provides Glimpse into the Future of Blood Cancer Treatment [Yahoo! Finance]Yahoo! Finance
- Royalty Pharma Announces Inaugural Prize for Impact in Healthcare [Yahoo! Finance]Yahoo! Finance
- Royalty Pharma Announces Inaugural Prize for Impact in HealthcareGlobeNewswire
- Royalty Pharma's (NASDAQ:RPRX) Profits May Not Reveal Underlying Issues [Yahoo! Finance]Yahoo! Finance
- Geron Secures $250M Funding and Strong Q3 Sales [Yahoo! Finance]Yahoo! Finance
RPRX
Sec Filings
- 11/8/24 - Form SC
- 11/6/24 - Form 10-Q
- 11/6/24 - Form 8-K
- RPRX's page on the SEC website